Be A Freedom Fighter · Bill Library

HR 10954 — Don't Flush Babies Act

Freedom score: -7 (scale −10 to +10)

Sponsor: Rep. Biggs, Sheri [R-SC-3] · Latest action: Referred to the House Committee on Energy and Commerce. (2026-11-05)

Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index

Findings — 21 highlighted provisions

Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.

  1. Sec. 4(a)(1)–(4) · Individual Rights — Abortion-drug providers must provide collection kits/instructions, obtain receipt acknowledgment, accept returned remains and waste and arrange burial/cremation and disposal; patients affected but not expressly required to return remains See in text ↓
  2. Sec. 4(c)(1)–(2) · Individual Rights — Provider must accept returns even from nonpatients See in text ↓
  3. Sec. 5 · Individual Rights — Existing emergency-treatment requirements preserved See in text ↓
  4. Sec. 4(d) · Individual Rights — Provider/kit-tampering violations carry imprisonment/fines See in text ↓
  5. Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain See in text ↓
  6. Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text See in text ↓
  7. Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display See in text ↓
  8. Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes See in text ↓
  9. Sec. 4(a)(1)–(4) · Economic Freedom — Kit, acknowledgment and disposal duties See in text ↓
  10. Sec. 4(b)(1)–(2) · Economic Freedom — Documentation identifies nearest receiving facility with contacts and approximate distance from patient address See in text ↓
  11. Sec. 4(c)(1)–(2) · Economic Freedom — Accepts returns regardless of patient relationship See in text ↓
  12. Sec. 4(d) · Economic Freedom — Up to five years imprisonment and $20,000–$150,000 fine per offense, or both, for covered dispensing without kit/documentation or tampering See in text ↓
  13. Sec. 4(e)(1)–(3) · Economic Freedom — Defines provider and kit components, separate leak-resistant containers, instructions, in-person returns and mail prohibition See in text ↓
  14. Sec. 4(a)(2) · Privacy and Due Process — Provider retains physical/electronic patient receipt acknowledgment See in text ↓
  15. Sec. 4(b)(2) · Privacy and Due Process — Address-dependent facility details See in text ↓
  16. Sec. 4(d) · Privacy and Due Process — Criminal penalties, without new special hearing or burden-of-proof rule See in text ↓
  17. Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions See in text ↓
  18. Sec. 4(a) · Government Power — HHS directs provider procedures See in text ↓
  19. Sec. 4(d) · Government Power — Criminal fines/imprisonment See in text ↓
  20. Sec. 5 · Government Power — Preserves emergency care laws See in text ↓
  21. Sec. 6 · Government Power — Packaging rule applies to drugs packaged 180 days after enactment; no express delay for Sec. 4. No sunset See in text ↓

Full text (introduced version)

30 of 35 text blocks highlighted. Source: GovInfo, fetched cached.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 10954 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 10954 To amend the Federal Food, Drug, and Cosmetic Act to deem an abortion drug misbranded unless it contains a ``Do Not Flush'' warning label and to require a catch kit, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES November 5, 2026 Mrs. Biggs of South Carolina (for herself and Mr. Cloud) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to deem an abortion drug misbranded unless it contains a ``Do Not Flush'' warning label and to require a catch kit, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Don't Flush Babies Act''.

SEC. 2. FINDINGS.

Congress finds the following:
(1) Clear and conspicuous packaging notices on chemical abortion drugs can reduce undignified disposition of aborted human fetal remains and improper disposal of solid medical waste.
(2) Standardized labeling requirements are commonly used in Federal product-safety legislation.
(3) Improper disposal of aborted human fetal remains and related solid medical waste may cause pipe blockages, plumbing damage, and environmental contamination.

SEC. 3. ABORTION DRUG WARNING LABEL REQUIREMENTS.

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following: ``(hh)(1) If it is an abortion drug, unless the packaging of such drug bears, in a clear, conspicuous, and prominent manner on the principal display panel--

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(A) a label notice with the following warning statement: `DO NOT FLUSH THE FETUS OR SOLID MEDICAL WASTE GENERATED BY USE OF THIS DRUG';

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(B) a symbol, to be located immediately adjacent to such label notice, that contains a pictorial image of a fetus at 10 weeks of gestation that displays the head, arms, and legs, placed so that the characteristics of the fetus are clearly visible and remain recognizable and, adjacent to such image, a pictorial image of a toilet that is recognizable, with such images centered inside a red circle with a diagonal red slash, styled as a standard `Do Not' symbol; and

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(C) under such symbol, the following statement: `Image shown is of a fetus at 10 weeks gestation; development of the fetus will vary by gestation. Discuss your gestation with your healthcare provider.'.

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(2) For the purposes of this paragraph, the label notice and symbol on the principal display panel of the packaging of an abortion drug shall be displayed in a type size, style, and placement, and in high contrast to the immediate background of the packaging of such abortion drug, such that an ordinary individual under customary conditions of purchase and use may see and read such label notice and symbol.

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(3) In this paragraph:

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(A) The term `abortion' means intentionally terminating the pregnancy of a woman known to be pregnant, with an intention other than-- ``(i) producing a live birth; ``(ii) removing a dead unborn child caused by miscarriage; or ``(iii) treating an ectopic or molar pregnancy.

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(B) The term `abortion drug' means-- ``(i) Mifeprex; ``(ii) Mifegyne; ``(iii) mifepristone; and ``(iv) any such other drug, substance, or combination of drugs or substances that is intended for use in carrying out an abortion.

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(C) The term `fetus' means the human product of conception from implantation until delivery.

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(D) The term `human fetal remains' means any whole fetus or part of the fetus.

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(E) The term `packaging' means the immediate container for an abortion drug and any outer container in which such drug is distributed.

Sec. 3, new FDCA §502(hh)(1)(A)–(C) · Economic Freedom — Abortion-drug packaging misbranded absent warning against flushing remains/waste, pictogram and gestational-development/consultation text

Sec. 3, new §502(hh)(2) · Economic Freedom — Prominent readable high-contrast display

Sec. 3, new §502(hh)(3)(A)–(F) · Economic Freedom — Defines abortion, covered drugs, fetus, fetal remains, packaging and waste, excluding miscarriage, ectopic/molar treatment and live-birth purposes

Sec. 3, new FDCA §502(hh) · Government Power — New federal misbranding conditions

``(F) The term `solid medical waste'-- ``(i) means the subset of medical waste consisting of non-liquid biological material generated by, and expelled in connection with, the use of an abortion drug; and ``(ii) does not include human fetal remains.''.

SEC. 4. CATCH KIT AND DISPOSAL REQUIREMENTS.

Sec. 4(a)(1)–(4) · Individual Rights — Abortion-drug providers must provide collection kits/instructions, obtain receipt acknowledgment, accept returned remains and waste and arrange burial/cremation and disposal; patients affected but not expressly required to return remains

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(a)(1)–(4) · Economic Freedom — Kit, acknowledgment and disposal duties

Sec. 4(a)(2) · Privacy and Due Process — Provider retains physical/electronic patient receipt acknowledgment

Sec. 4(a) · Government Power — HHS directs provider procedures

(a) Catch Kit Required.--The Secretary of Health and Human Services shall require an abortion provider who prescribes to, dispenses to, or otherwise encourages the use of an abortion drug by a patient for the purpose of carrying out an abortion, irrespective of the use for which the product is labeled, to--

Sec. 4(a)(1)–(4) · Individual Rights — Abortion-drug providers must provide collection kits/instructions, obtain receipt acknowledgment, accept returned remains and waste and arrange burial/cremation and disposal; patients affected but not expressly required to return remains

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(a)(1)–(4) · Economic Freedom — Kit, acknowledgment and disposal duties

Sec. 4(a) · Government Power — HHS directs provider procedures

(1) provide such patient with a catch kit and with documentation on the purpose and use of such catch kit;

Sec. 4(a)(1)–(4) · Individual Rights — Abortion-drug providers must provide collection kits/instructions, obtain receipt acknowledgment, accept returned remains and waste and arrange burial/cremation and disposal; patients affected but not expressly required to return remains

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(a)(1)–(4) · Economic Freedom — Kit, acknowledgment and disposal duties

Sec. 4(a)(2) · Privacy and Due Process — Provider retains physical/electronic patient receipt acknowledgment

Sec. 4(a) · Government Power — HHS directs provider procedures

(2) receive and retain a physical or electronic acknowledgment from such patient confirming receipt of such catch kit and documentation on the purpose and use of such catch kit;

Sec. 4(a)(1)–(4) · Individual Rights — Abortion-drug providers must provide collection kits/instructions, obtain receipt acknowledgment, accept returned remains and waste and arrange burial/cremation and disposal; patients affected but not expressly required to return remains

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(a)(1)–(4) · Economic Freedom — Kit, acknowledgment and disposal duties

Sec. 4(a) · Government Power — HHS directs provider procedures

(3) receive human fetal remains and solid medical waste returned by such patient, or an individual authorized by such patient to act on behalf of such patient, in accordance with the physical instructions provided with such catch kit; and

Sec. 4(a)(1)–(4) · Individual Rights — Abortion-drug providers must provide collection kits/instructions, obtain receipt acknowledgment, accept returned remains and waste and arrange burial/cremation and disposal; patients affected but not expressly required to return remains

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(a)(1)–(4) · Economic Freedom — Kit, acknowledgment and disposal duties

Sec. 4(a) · Government Power — HHS directs provider procedures

(4) arrange for the burial or cremation of such human fetal remains and the disposal of such solid medical waste.

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(b)(1)–(2) · Economic Freedom — Documentation identifies nearest receiving facility with contacts and approximate distance from patient address

Sec. 4(b)(2) · Privacy and Due Process — Address-dependent facility details

(b) Documentation Requirements.--The documentation provided with a catch kit under subsection (a) shall include--

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(b)(1)–(2) · Economic Freedom — Documentation identifies nearest receiving facility with contacts and approximate distance from patient address

(1) the name, address, and phone number of the nearest abortion facility or other facility equipped to receive aborted human fetal remains and solid medical waste in accordance with this section; and

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(b)(1)–(2) · Economic Freedom — Documentation identifies nearest receiving facility with contacts and approximate distance from patient address

Sec. 4(b)(2) · Privacy and Due Process — Address-dependent facility details

(2) the approximate distance of such facility from the address of such patient.

Sec. 4(c)(1)–(2) · Individual Rights — Provider must accept returns even from nonpatients

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(c)(1)–(2) · Economic Freedom — Accepts returns regardless of patient relationship

(c) Abortion Provider Requirements.--An abortion provider under subsection (a) shall, with respect to any patient who has used an abortion drug to carry out an abortion, regardless of whether such patient is a patient of such abortion provider--

Sec. 4(c)(1)–(2) · Individual Rights — Provider must accept returns even from nonpatients

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(c)(1)–(2) · Economic Freedom — Accepts returns regardless of patient relationship

(1) receive human fetal remains and solid medical waste from such patient, or an individual authorized by such patient to act on behalf of such patient, in accordance with the physical instructions provided with a catch kit; and

Sec. 4(c)(1)–(2) · Individual Rights — Provider must accept returns even from nonpatients

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(c)(1)–(2) · Economic Freedom — Accepts returns regardless of patient relationship

(2) arrange for the burial or cremation of such human fetal remains and the disposal of such solid medical waste.

Sec. 4(d) · Individual Rights — Provider/kit-tampering violations carry imprisonment/fines

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(d) · Economic Freedom — Up to five years imprisonment and $20,000–$150,000 fine per offense, or both, for covered dispensing without kit/documentation or tampering

Sec. 4(d) · Privacy and Due Process — Criminal penalties, without new special hearing or burden-of-proof rule

Sec. 4(d) · Government Power — Criminal fines/imprisonment

(d) Abortion Drug Disposition Violations.--Any person who prescribes or dispenses an abortion drug for the purpose of carrying out an abortion, irrespective of the use for which the product is labeled, without providing the catch kit and documentation required under this section, or who tampers with such catch kit, shall be imprisoned for not more than 5 years, fined not less than $20,000 and not more than $150,000, or both, for each offense.

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(e)(1)–(3) · Economic Freedom — Defines provider and kit components, separate leak-resistant containers, instructions, in-person returns and mail prohibition

(e) Definitions.--In this section:

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(e)(1)–(3) · Economic Freedom — Defines provider and kit components, separate leak-resistant containers, instructions, in-person returns and mail prohibition

(1) Abortion, abortion drug; human fetal remains; solid medical waste.--The terms ``abortion'', ``abortion drug'', ``human fetal remains'', and ``solid medical waste'' have the meanings given such terms in section 502(hh) of the Federal Food, Drug, and Cosmetic Act, as added by section 3.

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(e)(1)–(3) · Economic Freedom — Defines provider and kit components, separate leak-resistant containers, instructions, in-person returns and mail prohibition

(2) Abortion provider.--The term ``abortion provider'' means a person that performs abortions, including by prescribing or dispensing abortion drugs.

Sec. 4(a)–(e) · Property Rights — Regulates handling of biological material, not title or eminent domain

Sec. 4(e)(1)–(3) · Economic Freedom — Defines provider and kit components, separate leak-resistant containers, instructions, in-person returns and mail prohibition

(3) Catch kit.--The term ``catch kit'' means a packaged set of materials for use in collecting and containing aborted human fetal remains and solid medical waste generated by use of an abortion drug that includes the following: (A) A brightly colored, leak-resistant biohazardous collection container, to be labeled-- (i) in a contrasting color with the international biohazard symbol; and (ii) with the following statement: ``Human Fetal Remains''. (B) A brightly colored, leak-resistant biohazardous waste collection container, to be labeled-- (i) in a contrasting color with the international biohazard symbol; and (ii) with the following statement: ``Solid Medical Waste''. (C) Physical instructions for-- (i) the collection, containment, transportation, and disposal of solid medical waste; (ii) the cremation or burial of human fetal remains; and (iii) the in-person return of solid medical waste and human fetal remains by a patient, or an individual authorized by such patient to act on behalf of such patient, to an abortion provider. (D) A statement that any human fetal remains and solid medical waste generated by use of an abortion drug may not be returned to an abortion provider by mail.

SEC. 5. RULE OF CONSTRUCTION.

Sec. 5 · Individual Rights — Existing emergency-treatment requirements preserved

Sec. 5 · Government Power — Preserves emergency care laws

Nothing in this Act or the amendment made by this Act shall be construed to alter, supersede, or limit any requirement under Federal or State law related to emergency medical treatment.

SEC. 6. APPLICABILITY.

Sec. 6 · Government Power — Packaging rule applies to drugs packaged 180 days after enactment; no express delay for Sec. 4. No sunset

The amendment made by section 3 of this Act shall apply to an abortion drug that is packaged on or after the date that is 180 days after the date of enactment of this Act. <all>

Findings source: bill-scores-v2-batch24-findings-2026-11-14.md. Highlights come only from that file; no finding, score, or provision was invented for this page.

What you can do

Contact your U.S. Representative and Senators about this bill.

Find your Representative Contact your Senators

Spot an error on this page? Report it.